Table 2 Factors affecting poor response to Omalizumab or Benralizumab

Age

45

12.9

42.7

11.8

0.46

49.1

14.5

42.8

11.2

0.21

BMI

32.13

8.78

31.15

7.08

0.63

31.31

6.23

34.93

5.83

0.12

 F-sex

75

65.22

12

66.67

0.91

7

43.75

11

84.62

0.02

Current smoker

23

20

5

27.78

0.45

4

25

3

23.08

0.91

Childhood onset asthma

47

40.87

12

66.67

0.04

3

18.75

8

61.54

0.01

Comorbidity

DM

20

17.39

4

22.22

0.62

5

31.25

2

15.38

0.32

HTN

21

18.26

4

22.22

0.68

5

31.25

2

15.38

0.32

IHD

7

6.09

3

16.67

0.11

2

12.5

3

23.08

0.45

GERD

62

53.91

10

55.56

0.89

1

6.25

2

15.38

0.42

Obesity

18

15.65

3

16.67

0.91

11

68.75

7

53.85

0.41

AR

61

53.04

12

66.67

0.27

8

50

9

69.23

0.29

CRS

48

41.74

13

72.22

0.01

9

56.25

9

69.23

0.47

NP

26

22.61

5

27.78

0.63

7

43.75

5

38.46

0.77

Bronchiectasis

17

14.78

8

44.44

0.003

1

6.25

6

46.15

0.01

Eczema

4

3.48

1

5.56

0.52

1

6.25

2

15.38

0.42

Urticaria

10

8.7

2

11.11

0.66

0

0

1

7.69

0.44

ACT

Less Than 19

96

84.21

18

100

0.01

8

50

13

100

0.001

More than 20

18

15.79

0

0

8

50

0

0

FEV1%

More than 60%

63

54.78

6

33.33

0.05

8

50

2

15.38

0.04

Less than 60%

52

45.22

12

66.67

8

50

11

84.62

Total IgE (KU/L)

Below 220 KIU/L

46

41.07

10

55.56

0.04

4

25

6

53.85

0.22

From 221–700 KIU/L

46

41.07

2

11.11

4

25

3

23.08

More than 700 KIU/L

20

17.86

6

33.33

8

50

3

23.08

Blood Eosinophils

Less than 500 cells/mm³

25

43.86

6

46.15

0.88

2

12.5

7

53.85

0.01

More than 500 cells/mm³

32

56.14

7

53.85

14

87.5

6

46.15

FeNO (PPB)

Less than 25 (PPB)

28

66.67

2

50

0.51

5

31.25

6

46.15

0.52

More than 25 (PPB)

14

33.33

2

50

11

68.75

7

53.85

Maintenance OCS

3

2.61

4

22.22

0.006

0

0

3

23.08

0.02

Treatment shift

12

10.43

12

66.67

0.001

10

62.5

12

92.31

0.04

Treatment duration

7.87

2.96

8.39

2.2

0.38

5.63

1.07

4.11

1.12

0.19